Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2012 · third_quarter · 3T
Issues related to prevention, diagnosis and treatment of diabetes
Issues relating to Medicare Part D rebates
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Source: Senate LDA
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Safeguarding America's Pharmaceuticals Act of 2011
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R.1, American Recovery and Reinvestment Act S. Con. Res. 13 H. Con. Res. 85 FY10 Budget
Setting forth the congressional budget for the United States Government for fiscal year 2010 and including the appropriate budgetary levels for fiscal years 2009 and 2011 through 2014.
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1) S. Con. Res. 13, H. Con. Res. 85 Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010
Exclusivity, and damanges provisions in the Patent reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
S. 515, Patent reform Act of 2009 S. 610, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
S. 301, Physician Payments Sunshine Act of 2009 H.R. 1548, Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act S. 726, Promoting Innovation and Access to Life-Saving Medicine Act Drug Importation/Drug Safety H.R. 759, Food and Drug Administration Globalization Act of 2009
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Payment disclsoure regulations in the Physician Payments Sunshine Act of 2009 Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Regulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759) Drug Importation/Drug Safety
S. 301, Physician Payments Sunshine Act of 2009 H.R. 1548, Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act S. 726, Promoting Innovation and Access to Life-Saving Medicine Act Drug Importation/Drug Safety H.R. 759, Food and Drug Administration Globalization Act of 2009
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Payment disclsoure regulations in the Physician Payments Sunshine Act of 2009 Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Regulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759) Drug Importation/Drug Safety
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010 (no bill number) Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213)
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare Issues Reimbursement issues in Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Medicare provisions and Medicaid rebate issues in the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill, Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009- Comparative Effectiveness
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Reimbursement issues in the Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Chronic disease and diabetes care related provisions of the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill and Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes research Act of 2009- Comparative Effectiveness
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Reimbursement issues in the Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Chronic disease and diabetes care related provisions of the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill and Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes research Act of 2009- Comparative Effectiveness
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare Issues Reimbursement issues in Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Medicare provisions and Medicaid rebate issues in the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill, Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009- Comparative Effectiveness
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
America's Affordable Health Choices Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Food and Drug Administration Globalization Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
S. 301, Physician Payments Sunshine Act of 2009 H.R. 1548, Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act S. 726, Promoting Innovation and Access to Life-Saving Medicine Act Drug Importation/Drug Safety H.R. 759, Food and Drug Administration Globalization Act of 2009
Food and Drug Administration Globalization Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Payment disclsoure regulations in the Physician Payments Sunshine Act of 2009 Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Regulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759) Drug Importation/Drug Safety
Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare Issues Reimbursement issues in Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Medicare provisions and Medicaid rebate issues in the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill, Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009- Comparative Effectiveness
Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Reimbursement issues in the Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Chronic disease and diabetes care related provisions of the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill and Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes research Act of 2009- Comparative Effectiveness
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare Issues Reimbursement issues in Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Medicare provisions and Medicaid rebate issues in the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill, Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009- Comparative Effectiveness
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Reimbursement issues in the Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Chronic disease and diabetes care related provisions of the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill and Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes research Act of 2009- Comparative Effectiveness
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010 (no bill number) Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213)
Patient-Centered Outcomes Research Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Physician Payments Sunshine Act of 2009
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
S. 301, Physician Payments Sunshine Act of 2009 H.R. 1548, Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act S. 726, Promoting Innovation and Access to Life-Saving Medicine Act Drug Importation/Drug Safety H.R. 759, Food and Drug Administration Globalization Act of 2009
Exclusivity, and damanges provisions in the Patent reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
S. 515, Patent reform Act of 2009 S. 610, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
S. 515, Patent reform Act of 2009 S. 610, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Payment disclsoure regulations in the Physician Payments Sunshine Act of 2009 Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Regulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759) Drug Importation/Drug Safety
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Promoting Innovation and Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
S. 301, Physician Payments Sunshine Act of 2009 H.R. 1548, Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act S. 726, Promoting Innovation and Access to Life-Saving Medicine Act Drug Importation/Drug Safety H.R. 759, Food and Drug Administration Globalization Act of 2009
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
American Middle Class Tax (AMT) Relief Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
HR 1038, Access to Life-Saving Medicines Act, follow-on biologics HR 1561, Enhancing Drug Safety and Innovation Act of 2007 HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life Saving Medicine Act, follow-on biologics Drug Importation
Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596 Safe Internet Pharmacy Act of 2007, clinical trials, drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics Drug Importation H.R., Pathway for Biosimilars Act H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act Drug Imporation
Access to Life-Saving Medicine Act
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act
Enhancing Drug Safety and Innovation Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596 Safe Internet Pharmacy Act of 2007, clinical trials, drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics Drug Importation H.R., Pathway for Biosimilars Act H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Enhancing Drug Safety and Innovation Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
HR 1038, Access to Life-Saving Medicines Act, follow-on biologics HR 1561, Enhancing Drug Safety and Innovation Act of 2007 HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life Saving Medicine Act, follow-on biologics Drug Importation
Enhancing Drug Safety and Innovation Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act Drug Imporation
Enhancing Drug Safety and Innovation Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act
S.1145, Patent Reform Act of 2007, entire bill H.R.1908, Patent Reform Act of 2007, entire bill
S. 1145, Patent reform Act of 2007, entire bill H.R. 1908, Patent Reform Act of 2007, entire bill
S.1145, Patent Reform Act of 2007, entire bill H.R.1908, Patent Reform Act of 2007, entire bill S. 3600, Patent Reform Act of 2008, entire bill
S. 1145, Patent Reform Act of 2007, entire bill HR 1908, Patent Reform Act of 2007, entire bill
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act Drug Imporation
Patient Protection and Innovative Biologic Medicines Act of 2007
Client: AMYLIN PHARMACEUTICALS · Firm: AMYLIN PHARMACEUTICALS
HR 1038, Access to Life-Saving Medicines Act, follow-on biologics HR 1561, Enhancing Drug Safety and Innovation Act of 2007 HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life Saving Medicine Act, follow-on biologics Drug Importation
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2012 · second_quarter · Q2
Issues relating to Medicare Part D rebates
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Issues related to prevention, diagnosis and treatment of diabetes
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2012 · first_quarter · Q1
Issues relating to Medicare Part D rebates
Issues related to prevention, diagnosis and treatment of diabetes
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · fourth_quarter · Q4
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Issues relating to Medicare Part D rebates
Issues related to prevention, diagnosis and treatment of diabetes
Perscription Drug User Fee Act Reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · third_quarter · Q3
Issues related to the America Invents Act (S. 23, H.R. 1249)
FDA funding and agency effectiveness Potential Super Committee legislation affecting Medciare Part D and Medicaid rebates
Issues related to prevention, diagnosis and treatment of diabetes
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues Safeguarding America's Pharmaceuticals Act of 2011- H.R. 3026
Issues relating to Medicare Part D rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · second_quarter · Q2
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
FDA funding and agency effectiveness
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2011 · first_quarter · Q1
FDA funding and agency effectiveness
Exclusivity, damages, estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · fourth_quarter · Q4
Drug importation issues
Comparative effectiveness research and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · third_quarter · Q3
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Prescription drug issues Chronic disease and diabetes treatment issues within the Veterans Administration
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · second_quarter · Q2
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Prescription drug issues Chronic disease and diabetes treatment issues within the Veterans Administration
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2010 · first_quarter · Q1
Physician Payments Sunshine provision of HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to the expansion of Medicaid rebates in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 Provisions related to the expansion of Medicaid eligibility in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 Provisions related to Medicare Part D rebates in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · fourth_quarter · Q4
Provisions related to comparative effectiveness reserach in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Chronic disease and diabetes care related provisions in Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to comparative effectiveness reserach and reimbursement in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · third_quarter · 3A
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · third_quarter · Q3
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Chronic disease and diabetes care related provisions in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · second_quarter · Q2
Medicare Issues Reimbursement issues in Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Medicare provisions and Medicaid rebate issues in the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill, Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009- Comparative Effectiveness
Reimbursement issues in the Medicare Payment Advisory Commisssion (MedPAC) Reform Act of 2009 (S.1110) Chronic disease and diabetes care related provisions of the Affordable Health Choices Act (Senate), Americas Affordable Health Choices Act (H.R. 3200), Senate Finance Healthcare Reform Bill and Tri Caucus Healthcare Reform Bill H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes research Act of 2009- Comparative Effectiveness
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2009 · first_quarter · Q1
S. 515, Patent reform Act of 2009 S. 610, Patent Reform Act of 2009 H.R. 1260, Patent Reform Act of 2009
Labor Health Human Services Appropriations FY 2010 (no bill number)-provisions relating to Diabetes Research and Comparative Effectiveness
H.R.1, American Recovery and Reinvestment Act S. Con. Res. 13 H. Con. Res. 85 FY10 Budget
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2008 · fourth_quarter · Q4
H.R.5480, Medicare Funding Warning Response Act of 2008 H.R.2602, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R.4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions S.1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion S.2029, Physician Payments Sunshine Act of 2007 S.2662, Medicare Funding Warning Response Act of 2007 H.R.1424, Emergency Economic Stabalization Act of 2008 H.R.3162, Childrens Health and Medicare Protection Act of 2007 SCHIP (Senate), Medicare cuts to finance SCHIP expansion S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Extension of the R&D Tax Credit
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2008 · third_quarter · Q3
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act
Extension of the R&D Tax Credit
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2008 · second_quarter · Q2
H.R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R. 3162, Children's Health and Medicare Protection Act of 2007 H.R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions H.R. 5480, Medicare Funding Warning Response Act of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions SCHIP (Senate), Medicare cuts to finance SCHIP expansion H.R., Medicare Improvements for Patients and Providers Act of 2008 S. 3101, Medicare Improvements for Patients and Providers Act of 2008
H.R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H.R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596 Safe Internet Pharmacy Act of 2007, clinical trials, drug safety provisions S. 623, Access to Life-Saving Medicine Act, follow-on biologics Drug Importation H.R., Pathway for Biosimilars Act H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2008 · first_quarter · Q1
S. 1145, Patent Reform Act of 2007, entire bill HR 1908, Patent Reform Act of 2007, entire bill
Comparative Effectiveness Diabetes research issues LHHS appropriations
FY09 Adminstration Budget House Concurrent Resolution 312 FY09 Revised Congressional Budget Senate Concurrent Resolution 70 FY09 Congresisonal Budget Comparative Effectiveness FDA/drug importation
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2007 · mid_year · MA
Issues regarding implementation of Medicaid Part D Prescription Program; non-interference; HR4.
Issues regarding drug importation and general diabetes legislation.
Issues regarding HR 1908 and S 1145 dealing with patent reform legislation.
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2007 · year_end · YY
Issues regarding drug importation and general diabetes legislation.
Issues regarding the Prescription Drug User Fee Act (PDUFA) and drug safety.
Issues regarding H.R.1908 and S.1145 dealing with patent reform legislation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2007 · mid_year · MM
Issues regarding HR 1908 and S 1145 dealing with patent reform legislation.
Issues regarding the Prescription Drug User Fee Act [PDUFA] and drug safety.
Issues regarding drug importation and general diabetes legislation.
AMYLIN PHARMACEUTICALS via AMYLIN PHARMACEUTICALS
2006 · year_end · YY
Issues regarding implementation of Medicaid Part D Prescription Program.
Filing targets: Health & Human Services, Dept of (HHS)
Prevention, diagnosis and treatment of diabetes Diabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Exclusivity, damages,estoppel, post grant review and inter partes review provisions in the America Invents Act (S. 23, H.R. 1249)
Perscription Drug User Fee Act reauthorization FDA funding and agency effectiveness Drug importation issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prevention, diagnosis and treatment of diabetes Diabetes issues related to implementation of provisions of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Prescription drug issues Chronic disease and diabetes treatment issues within the Veterans Administration
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Provisions related to the expansion of Medicaid rebates in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to the expansion of Medicaid eligibility in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to Medicare Part D rebates Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Medicare and Medicaid provisions of H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010
Comparative effectiveness research and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Drug importation issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Provisions related to comparative effectiveness research in HR 3590 Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Chronic disease and diabetes care related provisions in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) Provisions related to comparative effectiveness reserach and reimbursement in Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Physician Payments Sunshine provision of Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010) FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Health care reform issues in H.R. 4872 Health Care Education and Reconciliation Act of 2010 related to Pub. L. 111-148 (Patient Protection and Affordable Care Act of 2010)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Chronic disease and diabetes care related provisions in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010 Provisions related to comparative effectiveness reserach and reimbursement HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Provisions related to comparative effectiveness research in HR 3590 the Patient Protection and Affordable Care Act and H.R.4872 the Health Care and Education Reconciliation Act of 2010
Exclusivity, damages and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Exclusivity, damanges and estoppel provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Provisions related to the expansion of Medicaid rebates in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to the expansion of Medicaid eligibility in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate Provisions related to Medicare Part D in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 Physician Payments Sunshine provision of Affordable Health Care for America Act (H.R. 3962)- House Physician Payments Sunshine provision of Patient Protection and Affordable Care Act (H.R. 3590)-Senate FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues in the Affordable Health Care for America Act (H.R. 3962)- House and the Patient Protection and Affordable Care Act (H.R. 3590)-Senate
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues
Exclusivity, and damanges provisions in the Patent Reform Act of 2009 (S. 515, H.R. 1260)
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Medicare provisions and Medicaid rebate issues in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009 H.R. 2502 Comparative Effectiveness Research Act of 2009 S. 1213 Patient Centered Outcomes Research Act of 2009 Provisions related to comparative effectiveness reserach and reimbursement in S. 1679, the Affordable Health Choices Act; America's Healthy Futures Act of 2009 (no bill number); H.R. 3200 America's Affordable Health Choices Act of 2009
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1)
Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010 (no bill number) Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213)
Payment disclsoure regulations in the Physician Payments Sunshine Act of 2009 Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Regulatory provisions in the Food and Drug Administration Globalization Act of 2009 (H.R. 759) Drug Importation/Drug Safety
Comparative effectiveness provisions in the American Recovery and Reinvestment Act (H.R. 1) S. Con. Res. 13, H. Con. Res. 85 Provisions relating to diabetes research and comparative effectiveness in the Labor Health Human Services Appropriations FY 2010
Exclusivity, and damanges provisions in the Patent reform Act of 2009 (S. 515, H.R. 1260)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 301, Physician Payments Sunshine Act of 2009 H.R. 1548, Pathway for Biosimilars Act H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act S. 726, Promoting Innovation and Access to Life-Saving Medicine Act Drug Importation/Drug Safety H.R. 759, Food and Drug Administration Globalization Act of 2009
Medicare Issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S.1145, Patent Reform Act of 2007, entire bill H.R.1908, Patent Reform Act of 2007, entire bill S. 3600, Patent Reform Act of 2008, entire bill
Comparative Effectiveness LHHS Appropriations Diabetes Research Issues H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act of 2009
H.R.1038, Access to Life-Saving Medicine Act, follow-on biologics H.R.1561, Enhancing Drug Safety and Innovation Act of 2007 H.R.1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S.1505, Affordable Biologics for Consumers Act, follow-on biologics S.1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S.596, Safe Internet Pharmacy Act of 2007 S. 623, Acces to Life-Saving Medicine Act, follow-on biologics H.R.5629, Pathway for Biosimilars Act H.R.5839, Safeguarding America's Pharmaceuticals Act Drug Imporation
FY09 Administration Budget House Concurrent Resolution 312 FY09 Revised Congressional Budget Senate Concurrent Resolution 70 FY09 Congresssional Budget Comparative Effectiveness FDA/ Drug Importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Comparative Effectiveness LHHS Appropriations Diabetes Research Issues H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act of 2009
FY09 Administration Budget House Concurrent Resolution 312 FY09 Revised Congressional Budget Senate Concurrent Resolution 70 FY09 Congresssional Budget Comparative Effectiveness FDA/ Drug Importation H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act of 2009
H.R.5480, Medicare Funding Warning Response Act of 2008 H.R.2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion H.R.4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions H.R.3162, Childrens Health and Medicare Protection Act of 2007 S.1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion S.2029, Physician Payments Sunshine Act of 2007 S.2662, Medicare Funding Warning Response Act of 2007 H.R.1424, Emergency Economic Stabalization Act of 2008
S.1145, Patent Reform Act of 2007, entire bill H.R.1908, Patent Reform Act of 2007, entire bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LHHS Appropriations Diabetes Research Issues Comparative Effectiveness
S. 1145, Patent reform Act of 2007, entire bill H.R. 1908, Patent Reform Act of 2007, entire bill
Extension of the R&D Tax Credit
Comparative Effectiveness FY09 Administration Budget House Concurrent Resolution 312, FY09 Revised Congressional Budget Senate Concurrent Resolution 70, FY09 Congressional Budget FDA/drug importation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HR 2606, 340B Program Improvement and Intergrity Act, 340B drug price expansion HR 3162, Children Health and Medicare Protection Act of 2007 HR 4, Medicare Precription Drug Price Negotiation Act, Medicare "non-interference" provisions HR 5480, Medicare Funding Warning Response of 2008 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion S. 2029, Physician Payments Sunshine Act of 2007 S. 2662, Medicare Funding Warning Response Act of 2008 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions SCHIP (Senate), Medicare cuts to finance SCHIP expansion
HR 1038, Access to Life-Saving Medicines Act, follow-on biologics HR 1561, Enhancing Drug Safety and Innovation Act of 2007 HR 1956, Patient Protection and Innovative Biologics Medicines Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions S. 623, Access to Life Saving Medicine Act, follow-on biologics Drug Importation
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues regarding implementation of Medicaid Part D Prescription Program; non-interference; HR4.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE